We previously reported the effect of VC in promoting checkpoint inhibitor immunotherapy efficacy using the B16-OVA melanoma syngeneic tumor model and that this is dependent on tumor-associated TET2 expression (38). The gene discussed is TET2; the disease is neoplasm.